bpc 157 и tb 500 BPC-157 + TB-500 Research Compound Capsules BPC-157 + TB-500 Peptides |

ISBN 978-0-443-07265-9

(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement

Hyperpigmentation of skin has been reported only rarely as the presenting manifestation of vitamin B 12 deficiency.[2] There is only one such Indian report.[3] A 34-year-old Indian male presented with darkening of skin and discoloration of hair and nails for two months

It is a small organic molecule (C18H14N2O2, MW 290.3 g/mol, CAS 303760-60-3) built on a benzohydrazide scaffold